abelacimab   Click here for help

GtoPdb Ligand ID: 12417

Synonyms: MAA-868 | MAA868 | NVS250519
Compound class: Antibody
Comment: Abelacimab (MAA868) is a humanized monoclonal antibody that binds to the catalytic domain of both coagulation factor XI (FXI, F11) and activated FXI (FXIa) [3], and which was designed for antithrombotic potential. It locks FXIa into a conformation that cannot be activated by FXIIa or thrombin [1-2]. Inhbiting FXI/FXIa produces anticoagulant effects without adversly affecting normal hemostasis. Anti-FXI mAbs offer an alternative FXI-targeting strategy to investigational small molecule FXI inhibitors like asundexian and milvexian. Osocimab is another clinical stage anti-FXI mAb.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Abelacimab has progressed to phase 3 clinical evaluations.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05171049 A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE Phase 3 Interventional Anthos Therapeutics, Inc.
NCT05171075 A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE Phase 3 Interventional Anthos Therapeutics, Inc.
NCT05712200 Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC) Phase 3 Interventional Anthos Therapeutics, Inc.